- Home
- NA vs TIL Comparison
NA vs TIL Comparison
Compare NA & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NA | TIL |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.4M | 74.7M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NA | TIL |
|---|---|---|
| Price | $2.95 | $8.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | ★ 47.5K | 38.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.54 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.75 | $5.67 |
| 52 Week High | $31.48 | $42.75 |
Technical Indicators
Market Signals| Indicator | NA | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 43.67 | 51.62 |
| Support Level | $2.78 | $8.14 |
| Resistance Level | $3.42 | $9.81 |
| Average True Range (ATR) | 0.15 | 0.55 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 31.24 | 40.81 |
Price Performance
Historical ComparisonAbout NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.